Immunohistochemistry in the era of personalised medicine

Clare Margaret McCourt, David Boyle, Jacqueline James, Manuel Salto-Tellez

Research output: Contribution to journalArticlepeer-review

37 Citations (Scopus)



Immunohistochemistry (IHC) plays a central role in the histopathological classification of diseases, including cancer. More recently, the importance of immunohistochemical staining is increasing. IHC usage in diagnostics is invaluable; however, the genetic and therapeutic significance of biomarker immunostaining has become equally relevant.


In this article, we would like to analyse the three distinct roles of IHC and review their individual impacts on modern diagnostic pathology: (1) diagnostic IHC; (2) genetic IHC and (3) therapeutic IHC.


Thus, we will characterise the different analytical processes that are required in the three approaches to IHC usage stated above, as well as the clinical significance and overall importance in patient management. This will allow us to hypothesise on the most appropriate laboratory environment and detection methods for the future.
Original languageEnglish
Pages (from-to)58-61
JournalJournal of Clinical Pathology
Issue number1
Early online date23 Dec 2012
Publication statusPublished - Jan 2013


  • Antineoplastic Agents
  • Pathology, Molecular
  • Receptor, erbB-2
  • Humans
  • Breast Neoplasms
  • Receptors, Steroid
  • Pathology, Surgical
  • Antibodies, Monoclonal
  • Laboratories, Hospital
  • Individualized Medicine
  • Lung Neoplasms
  • Tumor Markers, Biological
  • Carcinoma, Non-Small-Cell Lung
  • Immunohistochemistry
  • Female

ASJC Scopus subject areas

  • Pathology and Forensic Medicine


Dive into the research topics of 'Immunohistochemistry in the era of personalised medicine'. Together they form a unique fingerprint.

Cite this